Association of COVID-19 and Development of Type 1 Diabetes: A Danish Nationwide Register Study.

Autor:	Zareini B; Department of Cardiology, North Zealand Hospital, Hillerod, Denmark.; Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark., Sørensen KK; Department of Cardiology, North Zealand Hospital, Hillerod, Denmark.; Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark., Eiken PA; Department of Endocrinology, Bispebjerg Hospital, Copenhagen, Denmark., Fischer TK; Department of Clinical Research, North Zealand Hospital, Hillerod, Denmark., Kristensen PL; Department of Endocrinology and Nephrology, North Zealand Hospital, Hillerod, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Lendorf ME; Department of Oncology and Palliative Medicine, North Zealand Hospital, Hillerod, Denmark., Pedersen-Bjergaard U; Department of Endocrinology and Nephrology, North Zealand Hospital, Hillerod, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Torp-Pedersen C; Department of Cardiology, North Zealand Hospital, Hillerod, Denmark.; Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark., Nolsoe RLM; Department of Endocrinology and Nephrology, North Zealand Hospital, Hillerod, Denmark.
Jazyk:	angličtina
Zdroj:	Diabetes care [Diabetes Care] 2023 Aug 01; Vol. 46 (8), pp. 1477-1482.
DOI:	10.2337/dc23-0428
Abstrakt:	Objective: To compare the incidence of type 1 diabetes (T1D) before and during the coronavirus disease 2019 (COVID-19) pandemic and determine whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with T1D development. Research Design and Methods: All Danish residents aged <30 years free of diabetes from 2015 to 2021 were included. Individuals were followed from 1 January 2015 or birth until the development of T1D, the age of 30, the end of the study (31 December 2021), emigration, development of type 2 diabetes, onset of any cancer, initiation of immunomodulating therapy, or development of any autoimmune disease. We compared the incidence rate ratio (IRR) of T1D using Poisson regression models. We matched each person with a SARS-CoV-2 infection with three control individuals and used a cause-specific Cox regression model to estimate the hazard ratio (HR). Results: Among 2,381,348 individuals, 3,579 cases of T1D occurred. The adjusted IRRs for T1D in each quarter of 2020 and 2021 compared with 2015-2019 were as follows: January-March 2020, 1.03 (95% CI 0.86; 1.23); January-March 2021, 1.01 (0.84; 1.22), April-June 2020, 0.98 (0.80; 1.20); April-June 2021, 1.34 (1.12; 1.61); July-September 2020, 1.13 (0.94; 1.35); July-September 2021, 1.21 (1.01; 1.45); October-December 2020, 1.09 (0.91; 1.31); and October-December 2021, 1.18 (0.99; 1.41). We identified 338,670 individuals with a positive SARS-CoV-2 test result and matched them with 1,004,688 control individuals. A SARS-2-CoV infection was not significantly associated with the risk of T1D development (HR 0.90 [95% CI 0.60; 1.35]). Conclusions: There was an increase in T1D incidence during April-June 2021 compared with April-June 2015-2019, but this could not be attributed to SARS-CoV-2 infection. (© 2023 by the American Diabetes Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu